Ignite Creation Date:
2024-05-06 @ 3:03 AM
Last Modification Date:
2024-10-26 @ 11:27 AM
Study NCT ID:
NCT02196857
Status:
COMPLETED
Last Update Posted:
2020-01-14
First Post:
2014-07-18
Brief Title:
Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia AML and High Risk Myelodysplastic Syndrome MS With FLT3-ITD Mutation
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Organization Data
Organization:
MD Anderson Cancer Center
Class:
OTHER
Study ID:
2014-0076
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
MD Anderson Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Bayer | INDUSTRY |